Audio from Dr. Ira Jacobson on evidence for treating patients with immune-tolerant CHB and whether ALT 2 or more x ULN should define HBV treatment candidacy
Expert commentary from Christopher Byrne and Dr. John Dillon on evaluating an HCV treatment as prevention (TasP) model for PWID in Tayside, Scotland
CME/CE/CPE-certified video on HBV: Experts debate if/when to stop therapy, HCC screening frequency, the need for prophylaxis, and immune-tolerant CHB.
Linda M. Spooner, PharmD, BCPS, FASHP, FCCP, provides insights on how pharmacist medication therapy management expertise can improve HCV care
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.